Gapping down
In reaction to earnings/guidance:
- None
Other news:
- VYGR -9.4% (VYGR provides update on NBIb-1817 gene therapy program; FDA notified NBIX that it placed clinical hold on RESTORE-1 clinical trial)
- SPPI -8.5% (provides update on pre-NDA meeting for poziotinib; Cohort 3 of the ZENITH20 clinical trial did not meet its primary endpoint)
- NBIX -2.7% (VYGR provides update on NBIb-1817 gene therapy program; FDA notified NBIX that it placed clinical hold on RESTORE-1 clinical trial)
- TBIO -1.9% (CFO to depart)
- PII -1.4% (names interim CEO and interim CFO),
- CLDT -1% (files for $500 mln mixed securities shelf offering),
Analyst comments:
- FUBO -7% (downgraded to Market Perform from Outperform at BMO Capital Markets)
- PAYS -2.6% (downgraded to Hold from Buy at Canaccord Genuity)